Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [5] Core Insights - Domestic innovative drugs are expected to lead the tumor immunotherapy 2.0 era, with bispecific antibodies becoming a global focus and business development (BD) transaction volumes reaching new highs. The global value of Chinese innovative drugs is being rapidly uncovered [3][6] - A significant collaboration was established between Rongchang Biopharma and AbbVie, involving the PD-1/VEGF bispecific antibody (RC148), which includes a $650 million upfront payment and potential milestone payments of up to $4.95 billion, along with double-digit royalties on net sales outside Greater China. This partnership accelerates the internationalization of RC148 and highlights the potential of the tumor pipeline [6] - The report emphasizes the increasing interest from multinational pharmaceutical companies in domestic bispecific antibody drugs, indicating that these innovative drugs will be a key growth engine in the tumor immunotherapy 2.0 era [6] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry is positioned for growth, particularly in the area of innovative drugs and tumor immunotherapy [5] Investment Recommendations and Targets - Key investment targets include Rongchang Biopharma (688331), 3SBio (01530), 3SBio Guojian (688336), Innovent Biologics (01801), CanSino Biologics (09926), Kintor Pharmaceutical (06990), and Eucure Biopharma (09606), all of which are not rated yet [3] Recent Developments - The collaboration between Rongchang Biopharma and AbbVie is a pivotal event, marking a significant step in the global commercialization of innovative drugs [6]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company is expected to release profit elasticity in 2026 due to rising wool prices, with a resilient performance in 2025 despite industry pressures [4][8] - The company has adjusted its earnings forecast slightly, projecting earnings per share (EPS) of 0.62, 0.77, and 0.86 yuan for 2025-2027, respectively, with a target price of 10.54 yuan based on a 17x PE valuation for 2025 [5][9] Financial Performance Summary - Revenue is projected to grow from 4,438 million yuan in 2023 to 6,050 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 8.4% [6] - Operating profit is expected to increase from 484 million yuan in 2023 to 755 million yuan in 2027, reflecting a growth rate of 11.1% [6] - Net profit attributable to the parent company is forecasted to rise from 404 million yuan in 2023 to 624 million yuan in 2027, with a CAGR of 11.2% [6] - The gross margin is anticipated to improve from 18.6% in 2023 to 21.0% in 2027, indicating enhanced profitability [6] Market Performance Summary - The company's stock price as of January 13, 2026, is 8.9 yuan, with a target price of 10.54 yuan, suggesting a potential upside [1] - The stock has shown strong absolute performance over various time frames, including a 45.76% increase over the past year [1]

家电行业 行业研究 | 行业周报 AI 应用催化密集，AI+家电落地加速 核心观点 投资建议与投资标的 投资建议：内销方面，国补拉动效应虽边际放缓，但"两新"政策优化、延续，有望激 活家电更大消费潜能，白电龙头公司的一级能效产品占比更高，以旧换新内控管理流程 更成熟，受益更明显；出海仍为长期主线，多元化产能布局公司占优，看好家电龙头的 稳健经营能力。短期关注 CES2026 以及 AI 大模型对于智能消费硬件的催化。 主线一：龙头公司经营效率更高，海外产能布局更成熟，结合较高股息率可作为稳健配 置首选，相关标的：美的集团(000333，未评级)、海尔智家(600690，未评级)、海信视 像(600060，增持)。 主线二：出海仍为长期主线，展望 2026 年有望迎来估值切换，相关标的：石头科技 (688169，未评级) 原材料快速上涨导致利润承压、行业竞争加剧、AI 应用落地速度不及预期、关税扰动反 复等。 国家/地区 中国 行业 家电行业 报告发布日期 2026 年 01 月 13 日 看好（维持） | 曲世强 | 执业证书编号：S0860525100004 | | --- | --- | | | qush ...

渝农商行 601077.SH 公司研究 | 深度报告 | | 买入（维持） | | --- | --- | | 股价（2026年01月12日） | 6.51 元 | | 目标价格 | 8.29 元 | | 52 周最高价/最低价 | 7.68/5.43 元 | | 总股本/流通 A 股（万股） | 1,135,700/1,135,158 | | A 股市值（百万元） | 73,934 | | 国家/地区 | 中国 | | 行业 | 银行 | | 报告发布日期 | 2026 年 01 月 13 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | 1.4 | 3.01 | 0.31 | 14.48 | | 相对表现% | -0.13 | -1.55 | -3.44 | -13.85 | | 沪深 300% | 1.53 | 4.56 | 3.75 | 28.33 | | 屈俊 | 执业证书编号：S0860523060001 | | --- | --- | | | qujun@orientsec.com.cn | | ...

Core Insights - The report highlights that the market index has reached a volatile zone, but the underlying structure remains worthy of attention, indicating a healthy rotation in technology growth and cyclical stocks like non-ferrous metals and chemicals [2][3] - The report emphasizes a strategy focused on mid-cap blue chips as a stabilizing force, with technology growth providing support, particularly in sectors like smart vehicles and robotics [2][3] Industry Strategy - The non-ferrous metals sector is experiencing a price increase in lithium, driven by favorable tax policies and supply-demand dynamics, with lithium carbonate prices rising to $1,880 per ton, up $332 from the previous week [3] - The cobalt market is characterized by cautious purchasing strategies from downstream buyers, but tight supply conditions are supporting cobalt salt prices, indicating ongoing supply-demand negotiations [3] Thematic Strategy - The robotics sector is seeing increased catalysts, with the anticipated release of Tesla's Optimus V3 in Q1 2026 expected to boost attention on the robotics industry, alongside a significant number of domestic companies preparing for IPOs [4] - The report suggests that the domestic humanoid robot market is poised for substantial growth, with expected doubling of shipments and multiple companies likely to complete IPOs, benefiting from both domestic and international market developments [4]

| 配置关注权益商品，行业聚焦中盘蓝筹： | 2026-01-04 | | --- | --- | | ——资产配置月报 202601 | | | 权益、商品延续强势，风险资产占优： | 2025-12-30 | | 20251226 多资产配置周报 | | | 当低利率邂逅风偏回归，资产配置被动为 | 2025-12-12 | | 盾，主动为矛：——2026 年多资产配置展 | | | 望 | | | 交易平稳，预期主导：——资产配置月报 | 2025-12-03 | | 202512 | | | 资产配置策略中低波分化，行业策略转 | 2025-12-03 | | 向：——资产配置模型月报 202512 | | 资产配置 | 定期报告 国内风险评价稳步下行，A 股/商品占优 20260112 多资产配置周报 研究结论 报告发布日期 2026 年 01 月 13 日 | 郑月灵 | 执业证书编号：S0860525120003 | | --- | --- | | | zhengyueling@orientsec.com.cn | | | 021-63326320 | | 周仕盈 | 执业证书编号：S08601 ...

基金研究 | 定期报告 "资源品+军工制造"可能继续演绎，中盘 成长风格或占优 ETF 投资月报（2026 年第 1 期） 研究结论 风险提示 宏观经济风险、产业政策风险、行业周期风险、主题炒作风险、量化模型滞后性风险 等。本报告结论完全基于公开的历史数据进行计算，对基金产品和基金管理人的研究分 析结论并不预示其未来表现，也不能保证未来的可持续性，亦不构成投资收益的保证或 投资建议。本报告不涉及证券投资基金评价业务，不涉及对基金产品的推荐，亦不涉及 对任何指数样本股的推荐。 报告发布日期 2026 年 01 月 13 日 | 证券分析师 | | --- | 东春鸣 执业证书编号：S0860525100002 dongchunming@orientsec.com.cn 021-63326320 周期热度持续，关注化工主题基金：2026 年 01 月主动权益基金配置月观点 2026-01-08 中盘蓝筹风起，主动权益基金优势凸显： 市场有效性研究与主、被动基金配置建议 2026-01-06 公募量化基金定量跟踪月报（截至 2025 年 12 月底） 2026-01-05 有关分析师的申明，见本报告最后部分。其他重 ...

有色金属行业 行业研究 | 行业周报 退税政策催化，锂价再上涨 ——钴锂金属行业周报 核心观点 投资建议与投资标的 1 月仍看好碳酸锂价格上涨，中期需注意动力与储能端由于需求转淡带来的价格回踩压 力，但 2026 年锂价整体中枢上移的趋势不改。钴市在 2026 年 4 月大批量原料到港前， 受限于现货结构性紧缺与成本倒挂支撑，价格重心仍有上行空间。 风险提示 新能源汽车增速不及预期，储能装机增速不及预期。 国家/地区 中国 行业 有色金属行业 报告发布日期 2026 年 01 月 13 日 看好（维持） | 于嘉懿 | 执业证书编号：S0860525110005 | | --- | --- | | | yujiayi1@orientsec.com.cn | | | 021-63326320 | | 宁紫微 | 执业证书编号：S0860525120005 | | | ningziwei@orientsec.com.cn | | | 021-63326320 | 流动性预期强化，扩散行情延续：有色及 贵金属周报 2026-01-11 对标 2010 年，稀土板块有望迎来盈利估值 双击：——两用物项对日本出口管制政 ...

宏观经济 | 动态跟踪 就业增长强度过低，失业率难以维持稳 定，降息预期仍将修复 ——2025 年 12 月就业数据点评 研究结论 就业数据持续产生预期差的风险。 美国经济陷入衰退的风险。 通胀超预期上行的风险。 报告发布日期 2026 年 01 月 12 日 | 王仲尧 | 执业证书编号：S0860518050001 | | --- | --- | | | 香港证监会牌照：BQJ932 | | | wangzhongyao1@orientsec.com.cn | | | 021-63326320 | | 吴泽青 | 执业证书编号：S0860524100001 | | | wuzeqing@orientsec.com.cn | | | 021-63326320 | | 孙金霞 | 执业证书编号：S0860515070001 | | | sunjinxia@orientsec.com.cn | | | 021-63326320 | | 委内瑞拉事件对美国"例外溢价"或短多 | 2026-01-06 | | --- | --- | | 长空：——海外札记 20260105 | | | 美元周期还在探底，人民币升值 ...

Investment Rating - The report assigns a "Buy" rating for the company for the first time, with a target price of 42.63 CNY based on a valuation of 21 times earnings for 2026 [3][5]. Core Insights - The company is transitioning from a traditional home appliance manufacturer to a more diversified entity, leveraging its core competencies in refined management and strategic acquisitions [8][9]. - The company has completed the transfer of its overseas production capacity, which is expected to lead to improved profitability in the near future [8]. - The acquisition of Shanghai Pajie has enhanced the company's profitability in the automotive parts sector, with a strong order backlog [8][67]. - The PCBA business, acquired through the purchase of Lihua Technology, has broad downstream applications and is expected to contribute positively to revenue growth [8]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of 1.47 CNY, 2.03 CNY, and 2.37 CNY for the years 2025 to 2027, respectively [3]. - Revenue is expected to grow from 100.2 billion CNY in 2025 to 121.3 billion CNY in 2027, with a compound annual growth rate (CAGR) of 8.5% [11]. - The net profit attributable to the parent company is forecasted to be 8.4 billion CNY in 2025, increasing to 13.6 billion CNY by 2027 [11]. Business Overview - The company has diversified its operations into four main business segments: home appliances, automotive parts, electric motors, and PCBA manufacturing [10]. - The home appliance segment has seen a gradual decline in its revenue contribution, from 80% in 2019 to 58% in 2023, as the automotive and PCBA segments grow [29]. - The company maintains a strong focus on overseas markets, with approximately 70% of its revenue coming from exports [29]. Operational Performance - The company has demonstrated stable revenue growth, with a CAGR of 11.36% from 2019 to 2024, and net profit growth at a CAGR of 19.62% during the same period [36]. - The gross margin has remained stable, fluctuating between 20% and 30%, with recent strategic adjustments leading to an upward trend in profitability [39]. - The return on equity (ROE) is consistently high, projected to be between 25% and 30% from 2022 to 2024, indicating strong financial health compared to industry peers [42].